Skip to content
DataLookout
Menu

KANDLELIT-013NCT07431827

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 31 versions: 28 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 120 → 125 locations
  2. Minor Study sites: 120 to 122
  3. Minor Trial sites expanded: 115 → 120 locations
  4. Minor Study sites: 115 to 117
  5. Minor Trial sites expanded: 110 → 115 locations
  6. Minor Study sites: 110 to 112
  7. Minor Trial sites expanded: 106 → 110 locations
  8. Notable Eligibility criteria expanded, about 20 words
    • Trial sites expanded: 101 → 106 locations
    • Secondary endpoints: details revised at 2 of 11 entries
  9. Minor Trial sites expanded: 95 → 101 locationsv22
  10. Minor Trial sites expanded: 86 → 95 locationsv21
  11. Minor Trial sites expanded: 82 → 86 locationsv20
  12. Minor Trial sites expanded: 79 → 82 locationsv18
  13. Minor Trial sites expanded: 72 → 79 locationsv17
  14. Minor Trial sites expanded: 69 → 72 locationsv16
  15. Minor Trial sites expanded: 65 → 69 locationsv15
  16. Minor Trial sites expanded: 59 → 65 locationsv14
  17. Minor Study sites: 58 to 59v13
  18. Minor Study sites: 56 to 58v12
  19. Minor Trial sites expanded: 49 → 56 locationsv11
  20. Minor Trial sites expanded: 36 → 49 locationsv10
  21. Minor Trial sites expanded: 24 → 36 locationsv9
  22. Minor Trial sites expanded: 17 → 24 locationsv8
  23. Minor Study sites: 16 to 17v7
  24. Minor Study sites: 14 to 16v6
  25. Minor Trial sites expanded: 1 → 14 locationsv5
  26. Minor Interventions: MK-1084 (Drug), MK-3475A (Biological), Placebo (Drug) to Calderasib (Drug), MK-3475A (Biological), Placebo (Drug)
    • Study title expanded, about 1 word
    v4
  27. Notable Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 1, 2026 to Mar 18, 2026
    v2
  28. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Disease-free Survival (DFS)
Timeframe: Up to ~11 years

Secondary (11)

Overall Survival (OS)
Distant Metastasis-Free Survival (DMFS)
Lung Cancer Specific Survival (LCSS)
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Change from Baseline in the EORTC-QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Show 6 moreShow less
Change from Baseline in the EORTC-QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Change from Baseline in the EORTC-QLQ-C30 Dyspnea (Item 8) Score
Change from Baseline in the EORTC-Quality of Life Questionnaire-Lung Cancer 24 (QLQ-LC24) Coughing (Items 31 and 52) Combined Score
Change from Baseline in the EORTC-QLQ-LC24 Chest Pain (Item 40) Score
Number of Participants Who Experience an Adverse Event (AE)
Number of Participants Who Discontinue Study Treatment Due to an AE

Arms and interventions

Calderasib + MK-3475AExperimental

Participants receive calderasib daily (qd) and MK-3475A every 6 weeks (q6w) for up to 9 doses.

Placebo + MK-3475AActive comparator

Participants receive placebo qd and MK-3475A q6w for up to 9 doses.

Drugs: Calderasib, Placebo

Biologicals: MK-3475A

Sites

125 sites in 19 countries

China 27, Ukraine 15, Turkey (Türkiye) 11, Spain 9, Brazil 8, Japan 7, Greece 6, Colombia 5, South Korea 5, Taiwan 5, Argentina 4, Chile 4, France 4, Australia 3, Canada 3, Hong Kong 3, Italy 3, United Kingdom 2, Poland 1